Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunization
Healthy Volunteers

Interventions

BIOLOGICAL: mRNA NA vaccine
BIOLOGICAL: High Dose Quadrivalent Influenza Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company